Thiamine and spinocerebellar ataxia type 2

BMJ Case Reports

Volumn , Issue , 2013, Pages

  Costantini, Antonio ^a,b   Pala, Maria Immacolata ^a   Colangeli, Marco ^c,d   Savelli, Serena ^a  

^a Department of Neurological Rehabilitation   (Italy)

^b Università Cattolica di Roma   (Italy)

^c University Studies Abroad Consortium   (Italy)

^d UNIVERSITY OF TUSCIA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

COCARBOXYLASE; THIAMINE;

ADULT; ARTICLE; BRAIN ATROPHY; CASE REPORT; CLINICAL EVALUATION; DISEASE CLASSIFICATION; DISEASE SEVERITY; DRUG BLOOD LEVEL; DRUG MEGADOSE; DYSARTHRIA; FATIGUE; FATIGUE SEVERITY SCALE; FOLLOW UP; HUMAN; MALE; MEDICAL HISTORY; MOTOR DYSFUNCTION; NEUROIMAGING; NUCLEAR MAGNETIC RESONANCE IMAGING; OUTCOME ASSESSMENT; PATIENT ASSESSMENT; PATIENT MONITORING; PRIORITY JOURNAL; SLEEP DISORDERED BREATHING; SPINOCEREBELLAR DEGENERATION;

EID: 84872711305     PISSN: None     EISSN: 1757790X     Source Type: Journal    
DOI: 10.1136/bcr-2012-007302     Document Type: Article

References (15)

1. Fussi F, Cantagallo A. Profilo di Valutazione della Disartria, Adattamento Italiano del test di Robertson, raccolta di dati normative e linee di trattamento. Torino: Omega edizioni, 1999.
2. Brusse E, Brusse-Keizer MG, Duivenvoorden HJ, et al. Fatigue in spinocerebellar ataxia: patient self assessement of an early and disabling symptom. Neurology 2011;76:953-9.
3. Pedraza L, Botez MI. Thiamine status in inherited degenerative ataxias. J Neurol Neurosurg Psychiatry 1992;55:136-7.
4. Poloni M, Mazzarello P, Laforenza U, et al. Thiamin contents of cerebrospinal fluid, plasma and erythrocites in cerebellar ataxias. Eur Neurol 1992;32:154-8.
5. Bettendorff L, Mastrogiacomo F, LaMarche J, et al. Brain levels of thiamine and its phosphate esters in Friedreich's ataxia and spinocerebellar ataxia type 1. Mov Disord 1996;11:437-9. (Pubitemid 26235784)
6. Boesch SM, Wolf C, Seppi K, et al. Differentiation of SCA2 from MSA-C using proton magnetic resonance spectroscopic imaging. J Magn Reson Imaging 2007;25:564-9. (Pubitemid 46355419)
7. Lonsdale D. A review of the biochemistry, metabolism and clinical benefits of thiamin (e) and its derivatives. Evid Based Complement Alternat Med 2006;3:49-59. (Pubitemid 43999651)
8. Rindi G, Laforenza U. Thiamine intestinal transport and related issues: recent aspects. Proc Soc Exp Biol Med 2000;224:246-55. (Pubitemid 30643502)
9. Kono S, Miyajima H, Yoshida K, et al. Mutation in a thiamine-transporter gene and wernicke's-like encephalopathy. N Engl J Med 2009;360:1792-4.
10. Goodman & Gilman. The pharmacological basis of therapeutics. 10th edn. New York: McGraw-Hill, Inc., 2001.
11. Smithline HA, Donnino M, Greenblatt DJ. Pharmacokinetics of high-dose oral thiamine hydrochloride in healthy subjects. BMC Clin Pharmacol 2012;12:4.
12. Mastrogiacomo F, Kish SJ. Cerebellar alpha-ketoglutarate dehydrogenase activity is reduced in spinocerebellar ataxia type 1. Ann Neurol 1994;35:624-6. (Pubitemid 24153849)
13. Gispert S, Kurz A, Waibel S, et al. The modulation of amyotrophic lateral sclerosis risk by ataxin-2 intermediate polyglutamine expansion is a specific effect. Neurobiol Dis 2012;45:356-61.
14. Socal MP, Emmel VE, Reider CR, et al. Intrafamilial variability of Parkinson's phenotype in SCAs: novel cases due to SCA2 and SCA3 expansions. Parkinsonism Relat Disord 2009;15:374-8.
15. Jhala SS, Hazell AS. Modeling neurodegenerative disease pathophysiology in thiamine deficiency: consequences of impaired oxidative metabolism. Neurochem Int 2011;58:248-60.